Bionano Genomics Announces UK Footprint Expansion with Adoption of its Saphyr® System for Optical Genome Mapping in Two Genetic Laboratory Hubs within the United Kingdom’s National Health Service
Bionano Genomics (BNGO) announced the adoption of its Saphyr system by two genetics laboratory hubs in the UK's National Health Service (NHS) - Newcastle upon Tyne and Birmingham Women’s and Children’s Trusts. This adoption aims to evaluate optical genome mapping (OGM) versus traditional cytogenetic methods, enhancing BNGO's presence in the UK market. Previous placements in Belfast and London underscore growing interest. The OGM's potential lies in improving efficiency and detection capabilities for hematologic malignancies and other conditions, as mentioned by NHS leaders.
- Adoption of Saphyr system by two major NHS genetics laboratories, expanding market presence.
- Potential to improve efficiency and detection capabilities in analyzing chromosomal abnormalities.
- Risks associated with the adoption of new technology may impact initial results.
- Dependence on continued funding and support from NHS for sustained use of Saphyr.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the adoption of its Saphyr system by two genetics laboratory hubs (GLH) within the United Kingdom’s (UK) National Health Service (NHS). The Newcastle upon Tyne Hospitals NHS Foundation Trust and the Birmingham Women’s and Children NHS Foundation Trust intends to utilize the system to evaluate OGM against traditional cytogenetic methods.
The UK’s NHS is one of the world’s largest healthcare systems and is working to create a world class healthcare system using cutting edge genomic technologies. These adoptions significantly increase the footprint for OGM in the UK, complementing previous Saphyr placements in Belfast City Hospital in Belfast, Northern Ireland and Kings College Hospital in London, England.
The Newcastle upon Tyne Hospitals NHS Foundation Trust leads the North East and Yorkshire Genomic Laboratory Hub and is a partnership of hospitals and labs serving millions of people in these regions. The Birmingham Women’s and Children NHS Foundation Trust leads the Central and South Genomic Laboratory Hub and is a consortium of labs serving 12 million residents in West Midlands, Oxford and Wessex. Both labs intend to evaluate the potential of OGM to detect chromosomal aberrations in hematologic malignancies, genetic conditions and specific solid tumors.
“OGM has the potential to streamline a number of areas by replacing multiple analysis modalities with a single process,” said Polly Talley, FRCPath, scientific lead for HaemOnc at the North East and Yorkshire Genomic Laboratory Hub. “This could offer efficiency and speed to our genome analysis capabilities, and we are keen to see what this technology can provide to our HaemOnc service.” Ms. Talley’s colleague, Jennie Bell, Deputy Director/Consultant Clinical Scientist with the Central & South Genomic Laboratory Hub and Director, West Midlands Regional Genetics Laboratory, noted, “We were encouraged by the positive experience reported by other laboratories using OGM technology, which included good detection resolution for genomic structural variations, a high level of automation and genome-wide analysis.”
“With these two new Saphyr placements in the UK’s NHS, we continue to broaden our footprint and provide scientists and clinical researchers with the ability to develop a comprehensive, reliable and cost-effective solution for detecting chromosomal abnormalities in hematologic malignancies, genetic conditions and cancer research applications,” commented Erik Holmlin, PhD, President and Chief Executive Officer of Bionano. “We welcome these genomic laboratory hubs to the OGM community and look forward to working with them as we strive to transform the way the world sees the genome.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services, and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM and Saphyr® to analyze genomes in a comprehensive, reliable and cost-effective way, the potential for OGM to become part of the standard of care and NHS’ continued use of the Saphyr® system. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape, including the introduction of competitive technologies or improvements in existing technologies; failure of future results to support those found by NHS and referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions, including NHS, to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
Media Relations:
Michael Sullivan
Seismic
+1 (503) 799-7520
michael@teamseismic.com
FAQ
What is the significance of Bionano Genomics' announcement on February 2, 2022?
How does the Saphyr system compare to traditional cytogenetic methods?
Which NHS trusts have adopted the Saphyr system?
What are the potential risks associated with the implementation of the Saphyr system?
What are the applications of the Saphyr system?
